Nkarta Inc.   Report issue

For profit Phase 1
Founded: South San Francisco CA United States (2015)

Organization Overview

First Clinical Trial
2020
NCT04623944
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Nkarta Inc.

Active Ingredients

Drugs in Phase 1 Trials (2)

cd19 car-nk cells (1 trial)

nkx101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myelodysplastic Syndromes (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2